EUVIMEDSkopri EUVIMED
Open access

Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization

Shannon L Werner, Ryon P Graf, Mark Landers, David T Valenta, Matthew Schroeder, Stephanie B Greene, Natalee Bales, Ryan Dittamore, Dena Marrinucci

Journal of Circulating Biomarkers · 2015-11-02 · 4 · 3

DOI: 10.5772/60725 ↗

At a glance

Journal article in Journal of Circulating Biomarkers, published online on 2015-01-30. Written by Shannon L Werner and 8 co-authors. Institution: Epic Sciences, Inc., San Diego, CA, USA. Cited 108 times so far (Crossref); 78 references. The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The Epic Platform was developed for the unbiased detection and molecular characterization of circulating tumour cells (CTCs). Here, we report assay performance data, including accuracy, linearity, specificity and intra/inter-assay precision of CTC enumeration in healthy donor (HD) blood samples spiked with varying concentrations of cancer cell line controls (CLCs). Additionally, we demonstrate clinical feasibility for CTC detection in a small cohort of metastatic castrate-resistant prostate cancer (mCRPC) patients. The Epic Platform demonstrated accuracy, linearity and sensitivity for the enumeration of all CLC concentrations tested. Furthermore, we established the precision between multiple operators and slide staining batches and assay specificity showing zero CTCs detected in 18 healthy donor samples. In a clinical feasibility study, at least one traditional CTC/mL (CK+, CD45-, and intact nuclei) was detected in 89 % of 44 mCRPC samples, whereas 100 % of samples had CTCs enumerated if additional CTC subpopulations (CK-/CD45- and CK+ apoptotic CTCs) were included in the analysis. In addition to presenting Epic Platform's performance with respect to CTC enumeration, we provide examples of its integrated downstream capabilities, including protein biomarker expression and downstream genomic analyses at single cell resolution.

Subjects

Author keywords

Analytical ValidationBiomarkerCTCCTMCirculating Tumour CellsClinical FeasibilityEpic CTC PlatformFluid BiopsyLiquid BiopsyMetastasis

Authors and institutions

  • Epic Sciences, Inc., San Diego, CA, USA.

Cite

APA

Werner, S. L., Graf, R. P., Landers, M., Valenta, D. T., Schroeder, M., Greene, S. B., Bales, N., Dittamore, R., & Marrinucci, D. (2015). Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. Journal of Circulating Biomarkers, 4, 3. https://doi.org/10.5772/60725

Vancouver

Werner SL, Graf RP, Landers M, Valenta DT, Schroeder M, Greene SB, et al. Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. Journal of Circulating Biomarkers. 2015;4:3. doi:10.5772/60725

BibTeX
@article{Werner2015,
  author = {Werner, Shannon L and Graf, Ryon P and Landers, Mark and Valenta, David T and Schroeder, Matthew and Greene, Stephanie B and Bales, Natalee and Dittamore, Ryan and Marrinucci, Dena},
  title = {Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization},
  journal = {Journal of Circulating Biomarkers},
  year = {2015},
  volume = {4},
  pages = {3},
  doi = {10.5772/60725}
}
Start for free →